Login to Your Account

Ambrx, Zhejiang Hisun join forces to develop, co-market bispecifics

By Cornelia Zou
Staff Writer

Wednesday, April 30, 2014
HONG KONG – Ambrx Inc. and Zhejiang Hisun Pharmaceuticals Co. Ltd. (SH:600267) inked a deal to develop and commercialize bispecifics based on Ambrx's research with an aim to develop new oncology therapies.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription